文献速递肝病消化道肿瘤与早癌

乙型肝炎表面抗原清除后肝失代偿风险随时间下降但肝细胞癌风险未降

Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
PubMed 文献 · J Hepatol · 2022-12-02

基于香港全港数据库纳入9769例实现乙型肝炎表面抗原(HBsAg)清除的成年慢性乙型肝炎(CHB)患者,中位随访4.6年,106例(1.1%)发生肝细胞癌(HCC),124/9640例(1.3%)发生肝失代偿。HBsAg清除后0-7年与8-12年HCC累积发病率保持稳定(p=0.898),而肝失代偿累积发病率增长在8-12年减速(p=0.009)。多变量分析中HBsAg清除超过7年与肝失代偿风险降低相关(aSHR 0.55,95%CI 0.31-0.97,p=0.039),但与HCC风险无关(aSHR 1.35,95%CI 0.83-2.19,p=0.230)。

要点

  • HBsAg清除后HCC风险持续存在,尤其肝硬化患者。
  • HBsAg清除后肝失代偿风险随时间下降。
  • HBsAg清除超过7年与肝失代偿风险降低相关。

核心结论

  • HBsAg清除后患者HCC风险持续存在,而肝失代偿风险随时间下降。
  • CHB患者HBsAg血清学清除后12年仍有不可忽视的HCC风险,尤其肝硬化者。
  • 临床实践中,HBsAg清除的CHB患者临床结局优于持续感染者,但肝硬化及其他高危亚组在HBsAg清除后仍需要长期HCC监测。

研究设计与样本

  • 利用香港全港数据库识别2000年1月至2020年12月间实现HBsAg清除的成年CHB单一感染患者。
  • 排除HBsAg血清学清除前或随访不足6个月接受肝移植和/或发生HCC者。
  • 共纳入9769例实现HBsAg清除的CHB患者,平均年龄57岁,男性60.0%,肝硬化13.2%,HBsAg丢失时多数肝功能代偿。
  • 主要终点为HCC,次要终点为肝失代偿。

主要发现

  • 中位随访4.6年(第25-75百分位2.2-8.4年),106例(1.1%)发生HCC。
  • 发生HCC者较未发生者年龄更大、更可能为男性且肝硬化、HBsAg丢失时丙氨酸氨基转移酶更高且血小板更低。
  • HBsAg丢失后0-7年与8-12年HCC累积发病率保持稳定(p=0.898)(粗年发病率下降:-0.04%,95%CI -0.13%至0.04%,p=0.265)。
  • 124/9640例(1.3%)发生肝失代偿,HBsAg丢失后8-12年肝失代偿累积发病率增长减速(p=0.009)(粗年发病率下降:-0.23%,95%CI -0.40%至-0.06%,p=0.012)。
  • 多变量分析中HBsAg丢失超过7年与肝失代偿风险降低相关(aSHR 0.55,95%CI 0.31-0.97,p=0.039),但与HCC无关(aSHR 1.35,95%CI 0.83-2.19,p=0.230)。

临床怎么用

  • 临床实践中,HBsAg清除的CHB患者临床结局优于持续感染者,但肝硬化及其他高危亚组在HBsAg清除后仍需要长期HCC监测。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We examined the long-term incidence of hepatocellular carcinoma (HCC) and hepatic decompensation among chronic hepatitis B (CHB) patients who have achieved hepatitis B surface antigen (HBsAg) seroclearance. METHODS: All adult CHB-monoinfected patients who cleared HBsAg between January 2000 and December 2020 were identified using a territory-wide database in Hong Kong. Patients who underwent liver transplantation and/or developed HCC before HBsAg seroclearance or less than 6 months follow-up were excluded. The primary and secondary endpoints were HCC and hepatic decompensation respectively. RESULTS: We identified 9,769 patients with CHB who achieved HBsAg seroclearance (mean age 57 years, 60.0% male, 13.2% cirrhosis); most had compensated liver function at HBsAg loss. At a median (25th-75th percentile) follow-up of 4.6 (2.2-8.4) years, 106 (1.1%) patients developed HCC. Patients who developed HCC were older, more likely to be male and have cirrhosis, and had higher alanine aminotransferase and lower platelets at the time of HBsAg loss than patients without HCC. The cumulative incidence of HCC remained steady 0-7 and 8-12 years after HBsAg loss (p = 0.898) (crude annual incidence drop: -0.04%, 95% CI -0.13% to 0.04%, p = 0.265). Moreover, 124/9,640 (1.3%) patients developed hepatic decompensation. The growth in cumulative incidence of hepatic decompensation decelerated 8-12 years after HBsAg loss (p = 0.009) (crude annual incidence drop: -0.23%, 95% CI -0.40% to -0.06%, p = 0.012). In multivariable analysis, HBsAg loss for over 7 years was associated with a reduced risk of hepatic decompensation (adjusted subdistribution hazard ratio [aSHR] 0.55, 95% CI 0.31-0.97, p = 0.039) but not HCC (aSHR 1.35, 95% CI 0.83-2.19, p = 0.230). CONCLUSION: HCC risk persists in patients after HBsAg loss, whereas the risk of hepatic decompensation decreases over time. IMPACT AND IMPLICATIONS: Patients with chronic hepatitis B (CHB) still have a non-negligible risk of hepatocellular carcinoma (HCC) after 12 years of HBsAg seroclearance, especially among those with cirrhosis. The risk of developing hepatic decompensation decreases over time after HBsAg seroclearance. In clinical practice, although patients with CHB who cleared HBsAg have a more favourable clinical outcome than those who remain chronically infected, long-term HCC surveillance would still be necessary for patients with cirrhosis and other high-risk subgroups after HBsAg seroclearance.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Yip TC, Wong VW, Lai MS, et al. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss. J Hepatol. 2022. PMID: 36463985. doi:10.1016/j.jhep.2022.11.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。